다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

BIIB

Biogen (BIIB)

Biogen Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:BIIB

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/10	06:57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/12/10	06:56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/12/10	00:33	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BIIB	Biogen Inc
2024/12/05	08:31	PR Newswire (US)	"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico	NASDAQ:BIIB	Biogen Inc
2024/11/28	09:31	PR Newswire (US)	"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea	NASDAQ:BIIB	Biogen Inc
2024/11/19	15:00	GlobeNewswire Inc.	Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity	NASDAQ:BIIB	Biogen Inc
2024/11/15	03:29	PR Newswire (US)	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease	NASDAQ:BIIB	Biogen Inc
2024/11/15	01:23	GlobeNewswire Inc.	Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease	NASDAQ:BIIB	Biogen Inc
2024/11/08	06:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/11/05	06:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/10/31	08:30	GlobeNewswire Inc.	Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference	NASDAQ:BIIB	Biogen Inc
2024/10/31	05:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIIB	Biogen Inc
2024/10/31	05:31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BIIB	Biogen Inc
2024/10/30	19:55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIIB	Biogen Inc
2024/10/30	19:37	IH Market News	US Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge Up	NASDAQ:BIIB	Biogen Inc
2024/10/30	07:00	GlobeNewswire Inc.	Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases	NASDAQ:BIIB	Biogen Inc
2024/10/29	21:00	GlobeNewswire Inc.	Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer	NASDAQ:BIIB	Biogen Inc
2024/10/28	21:30	GlobeNewswire Inc.	Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025	NASDAQ:BIIB	Biogen Inc
2024/10/27	09:15	GlobeNewswire Inc.	Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024	NASDAQ:BIIB	Biogen Inc
2024/10/24	20:30	GlobeNewswire Inc.	Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference	NASDAQ:BIIB	Biogen Inc
2024/10/22	20:30	GlobeNewswire Inc.	Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024	NASDAQ:BIIB	Biogen Inc
2024/10/09	20:30	GlobeNewswire Inc.	Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients	NASDAQ:BIIB	Biogen Inc
2024/10/08	20:30	GlobeNewswire Inc.	New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA	NASDAQ:BIIB	Biogen Inc
2024/10/08	08:08	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/09/24	14:00	GlobeNewswire Inc.	UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024	NASDAQ:BIIB	Biogen Inc
2024/09/12	20:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BIIB	Biogen Inc
2024/09/12	20:30	GlobeNewswire Inc.	Biogen Board Appoints Two New Independent Directors	NASDAQ:BIIB	Biogen Inc
2024/09/05	19:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/09/04	20:30	GlobeNewswire Inc.	Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA	NASDAQ:BIIB	Biogen Inc
2024/09/04	02:00	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BIIB	Biogen Inc

검색 관련기사 보기:NASDAQ:BIIB

1 2 3 4 5 6 7 8 9 10 다음 >>

American Express

US Dollar vs Euro

US Dollar vs Yen

Invesco QQQ Trust Series 1

Verizon Communications

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관